Table 1 (abstract P1). Treatment emergent adverse event and serious adverse event
From: Sepsis 2018
Patients with at least one | PlaceboN=12 | 0.3N=13 | 1.0N=12 | 3.0N=12 | TotalN=49 |
|---|---|---|---|---|---|
TEAE | 10 (83.3%) | 12 (92.3%) | 12 (100.0%) | 11 (91.7%) | 45 (91.8%) |
Severe TEAE | 8 (66.7%) | 6 (46.2%) | 5 (41.7%) | 4 (33.3%) | 23 (46.9%) |
TEAE related to the study drug | 2 (16.7%) | - | 2 (16.7%) | - | 4 (8.2%) |
Serious AE incl. death | 7 (58.3%) | 4 (30.8%) | 2 (16.7%) | 4 (33.3%) | 17 (34.7%) |